Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study
1 Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain. FCERVAN@clinic.cat.
2 Royal Adelaide Hospital and Flinders Medical Centre, Adelaide, SA, Australia.
3 University Hospital Sveti Ivan Rislki, Sofia, Bulgaria.
4 IRCCS Azienda Ospedaliero-Universitaria di Bologna, Institute of Hematology "Seràgnoli", Bologna, Italy.
5 Department of Hematology, V.A. Baranov Republican Hospital, Petrozavodsk, Russian Federation.
6 CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, AOU Careggi, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
7 Hematology Service, ZNA Stuivenberg, Antwerp, Belgium.
8 Department of Internal Medicine I, Division of Hematology and Hemostaseology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.
9 Juntendo University School of Medicine, Tokyo, Japan.
10 St Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.
11 University of Insubria, Varese, Italy.
12 Novartis Pharma, East Hanover, NJ, USA.
13 Novartis Healthcare Pvt. Ltd, Hyderabad, India.
14 Novartis Pharma AG, Basel, Switzerland.
15 University Hospital Halle, Halle (Saale), Germany.